Leaders in early detection and top scientists and innovators in cancer research and bioengineering will gather in Portland, Oregon, Oct. 18-20, 2022, for the seventh in the series organized by the OHSU Knight Cancer Institute and Cancer Research UK, joined in 2018 by the Canary Center at Stanford.
The conference is part of a long-term commitment to understand the biology behind early stage cancers, find new detection and screening methods, and enhance uptake and accuracy of screening.
- Mechanistically-informed early detection
- What is needed for an early detection/diagnostic test to reach clinical practice?
- Microbiological risk factors for early detection
- Emerging technologies for early detection
The lineup of speakers already includes:
John Carpten, Ph.D., USC Norris Comprehensive Cancer Center, one of the discoverers of the first true hereditary prostate cancer gene, and a pioneer in exploring the role of biology in disparate cancer incidence and mortality among underrepresented populations.
Wendy Garrett, M.D., Ph.D., Harvard School of Public Health, an expert on host-microbiota interactions, whose research is revealing how gut microbes might shed light on cancer development and cancer treatments.
Nora Pashayan, M.D., Ph.D., University College London, who is advancing risk-tailored cancer screening by integrating genomics and epigenomics for risk stratification.
Victor Velculescu, M.D., Ph.D., Johns Hopkins Kimmel Cancer Center, known for discoveries in cancer genomics, his group has developed non-invasive liquid biopsy approaches for cancer early detection and monitoring.